Short Answer
There is no single standard cost or duration for a medical-AI clinical validation study; both are determined by scope. The main drivers of cost and duration are: the study type (retrospective standalone, prospective, or multi-reader reader study), the primary endpoint and the associated sample size / power calculation, the difficulty of constructing the reference standard (ground truth), whether it is single-center or multi-center, whether external validation is required, and the target regulator (TITCK, EU-MDR, FDA). To these are added the readiness of the data and the ethics committee timeline. That is why the right question is not "how much will it cost" but "what is the minimum defensible evidence required for our intended use and regulatory target." The most expensive study is the one that has to be redone because its scope was set up incorrectly.
Serteser Danismanlik is run by a biomedical engineer (BME MSc) who has developed a medical-AI medical device and published it in a peer-reviewed international journal. It clarifies the minimum defensible validation scope required for your device's intended use and regulatory target, designs the study accordingly, and conducts it as a named methodologist.
"How much does clinical validation cost, and how long does it take?" is a natural and legitimate question, but it cannot be answered with a single number: because both cost and duration derive from the scope of the study, and scope varies from device to device. Two devices may have the same accuracy, but one can be defended with a single-center retrospective study while the other requires a multi-center prospective study; between them there is a several-fold difference in both cost and timeline.
Rather than giving a figure, this article explains the drivers that actually determine cost and duration, so that you can set the right expectation and the right scope for your own device.
The Drivers That Determine Cost
A few fundamental decisions determine the budget of a validation study:
- Study type: A retrospective standalone performance study (using existing, labeled data) is the most economical. Prospective data collection or a multi-reader reader study (MRMC) comes into play when it is necessary to measure the impact on the clinician workflow, and it raises the cost significantly.
- Sample size: It is not "all the cases we have" but a formal power calculation that estimates the primary endpoint (for example AUC or sensitivity at a fixed threshold) with the targeted precision. What is often binding is not the total N but the number of positive cases (events); for rare findings, the required data volume grows rapidly.
- Construction of the reference standard: The "harder" the ground truth is (histopathology, follow-up outcome, or multi-expert consensus), the stronger but also the more costly it is. In consensus readings, the number of readers, the agreement rule, and the measurement of inter-observer agreement all mean additional effort.
- Number of centers: A single-center study is fast and cheap but has limited generalizability. A multi-center design captures device/manufacturer and population diversity and strengthens external validity, but it adds coordination and cost.
- External validation: An independent data set from a separate center or time period, tested without retraining the model, is the evidence that regulatory files actually expect. When required, it increases scope and cost, but in most cases it is not negotiable.
- Regulatory target: The evidence threshold and reporting expected by TITCK/EU-MDR and FDA files (TRIPOD-AI, STARD-AI, MDCG 2020-1 three-component clinical evaluation) shape the scope.
The Drivers That Determine Duration
The timeline more often stems not from the statistics but from preparation and process:
- Data readiness: If the data is already collected, anonymized, and labeled, the study proceeds quickly. Raw, disorganized, or data not yet anonymized from a KVKK perspective means a curation effort that takes weeks to months before analysis.
- Ethics committee and permissions: The ethics committee approval and institutional permissions required by prospective or defined data use are a fixed part of the timeline.
- Reference standard adjudication: Multi-expert reading and dispute resolution is the step that lengthens the timeline but determines quality.
- Retrospective or prospective: While a retrospective study can be concluded within weeks to months using existing data, prospective data collection takes much longer depending on patient flow.
The Most Expensive Study Is the One That Has to Be Redone
What truly inflates the cost is often not the study itself but its repetition because it was set up incorrectly. If the analysis plan was written after the data, if the model was tuned during validation (meaning development was actually being done), if the reference standard is not independent of the model's label, or if external validation was never designed, then the regulator or reviewer rejects the study and has to request it from scratch. At that point, both money and months are spent twice.
That is why the cheapest validation is the one whose scope is set up correctly from the start: a pre-locked protocol, an independent reference standard, and the minimum evidence required as defined by the intended use. To clarify this minimum defensible scope for your device, you can request a 15-minute free scoping.
What Does Scoping Clarify?
A proper scoping conversation, before giving a price, answers these questions: what is your intended use and target class; which metric should be the primary endpoint; how many positive cases does the sample size calculation require; how will the reference standard be constructed; is external validation required; and against which regulatory target will it be reported. Once these questions are clear, cost and duration become predictable; any figure given before they are clear is either too high or too low.
Conclusion: Scope First, Figure Second
The cost and duration of clinical validation depend not on how good your device is, but on the scope of evidence required by your intended use. The correct order is to first set the scope according to intended use and regulatory target, then place cost and timeline on top of it. Reversing this order, that is, first fixing the budget and then trying to fit the scope into it, is the starting point of most rejected validation files.